The end of Qutenza sends NGX-1998 into the neuropathic pain fray
This article was originally published in Scrip
Executive Summary
Following the FDA's rejection of Qutenza (8% capsaicin patch) for the management of HIV-related pain, potential for the product in the future neuropathic pain market will remain limited to postherpetic neuralgia. NeurogesX will shift its focus to the development of NGX-1998 - a more user-friendly, liquid formulation of the drug. However, the shift towards an early pipeline product means that NeurogesX will have to face greater competition in the future neuropathic pain market as a number of agents are topical pipeline agents will provide fierce competition.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.